Celavie Biosciences Applications
Celavie Biosciences is committed to relieving suffering across the globe with regenerative stem cell therapies that address the following diseases of the central nervous system and other disorders.
Diseases of the Central Nervous System
According to the World Health Organization, 7.1% of the global burden of disease stems from central nervous system neurological disorders and cerebrovascular disease.
Parkinson’s disease (PD) is a chronic and progressive movement disorder. More than 6 million people worldwide are living with Parkinson’s disease.1 The risk of developing Parkinson’s is about 1% at age 60.2 The cause is unknown, and there is no cure at this time.
PD is characterized by:
- Death of neurons that produce dopamine—a chemical that controls movement and coordination
- Lack of ability to control movement normally, especially as the disease progresses
Huntington’s disease (HD) is a progressive neurodegenerative disorder causing an abnormal expansion of IT-15 gene on chromosome 4. Most people develop Huntington’s disease between 30-54 years old, but HD can manifest as early as 4 years old and as late as 80 years. Individuals with the adult-onset form of HD usually live about 15 to 20 years after signs and symptoms begin. Huntington’s disease is most common in populations of European descent and affects 25,000 to 30,000 individuals in the US.3
Huntington’s disease often includes some or all of the following symptoms:
- Early signs including depression, poor coordination, and trouble learning new information or making decisions
- Involuntary jerking or twitching movements, known as chorea, which become more pronounced as the disease progresses
- Trouble walking, speaking, and swallowing
- Changes in personality and a decline in thinking and reasoning abilities
Spinocerebellar Ataxias (SCA)
The the SCAs are a highly heterogeneous group of disorders phenotypically characterized by gait ataxia, incoordination of eye movements, speech, and hand movements, and usually associated with atrophy of the cerebellum. Currently, there are 48 genetically distinct subtypes of SCA. SCAs are numbered in the chronological order in which the causative gene of the subtype was identified. The term spinocerebellar was chosen to represent the concomitant involvement of the spinal cord and the cerebellum in these diseases. Their hallmark symptom is slowly progressive, symmetrical, midline and limb ataxia, with characteristic loss of accuracy (dysmetria), rhythm (dysdiadochokinesis), and speed of movement, affecting eye movements, speech and swallowing, hand and foot coordination, station, and gait.4
Epilepsy is a central nervous system disorder in which nerve cell activity in the brain becomes disrupted, causing seizures. More than 23 million individuals worldwide suffer from epileptic seizures.1 Treatment with medication or surgery can control seizures for approximately 80% of people with epilepsy. Some children with epilepsy may outgrow the condition.
Seizure symptoms vary widely, but can include:
- Staring blankly for a few seconds
- Repeatedly twitching arms or legs
- Loss of consciousness
Celavie is committed to using our allogeneic pluripotent stem cell technology to alleviate suffering for a multitude of other disorders as well.
Second-degree burns affect both the epidermis and the second layer of skin, the dermis. Blisters may develop and pain can be severe. Deep second-degree burns can cause scarring. Third-degree burns reach the fat layer beneath the skin. These burns can destroy nerves, causing numbness and often lead to permanent disfigurement. The WHO estimated that, in 2014 alone, nearly 11 million people worldwide required medical attention for burn injuries.
- GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Lond. Engl. 388, 1545–1602 (2016).
- Truong, D. D., Bhidayasiri, R., Lisak, R. P. & Carroll, W. M. International Neurology. (Wiley Blackwell, 2016).
- Frank, S. Treatment of Huntington’s disease. Neurother. J. Am. Soc. Exp. Neurother. 11, 153–160 (2014).
- Sheng-Han Kuo, Ataxia; Continuum (Minneapolis MN) 2019;25 (4, MOVEMENT DISORDERS): 1036–1054